Results 321 to 330 of about 3,954,159 (357)
Some of the next articles are maybe not open access.
2016
he use of corrosion inhibitors represents an important option for the control of corrosion processes and for providing corrosion protection to different metals. Inhibitors have been widely used for corrosion control. They can be employed in solution in order to control the aggressiveness of a corrosive media.
ANDREATTA, Francesco, FEDRIZZI, Lorenzo
openaire +2 more sources
he use of corrosion inhibitors represents an important option for the control of corrosion processes and for providing corrosion protection to different metals. Inhibitors have been widely used for corrosion control. They can be employed in solution in order to control the aggressiveness of a corrosive media.
ANDREATTA, Francesco, FEDRIZZI, Lorenzo
openaire +2 more sources
Clinics in Liver Disease, 2009
The percentage of patients chronically infected with hepatitis C virus (HCV) who have reached sustained antiviral response has increased since the introduction of the pegylated interferon-alpha (pIFNa) and ribavirin (RBV) treatment. However, the current standard pIFNa/RBV therapy not only has a low success rate (about 50%) but is often associated with ...
openaire +2 more sources
The percentage of patients chronically infected with hepatitis C virus (HCV) who have reached sustained antiviral response has increased since the introduction of the pegylated interferon-alpha (pIFNa) and ribavirin (RBV) treatment. However, the current standard pIFNa/RBV therapy not only has a low success rate (about 50%) but is often associated with ...
openaire +2 more sources
PI3K inhibitors are finally coming of age
Nature Reviews Drug Discovery, 2021Bart Vanhaesebroeck +2 more
exaly
2012
In May 2003, the US Food and Drug Administration (FDA) granted accelerated approval for the use of the first-in-class proteasome inhibitor bortezomib as a third-line therapy in multiple myeloma, and the European Union followed suit a year later. Bortezomib has subsequently been approved for multiple myeloma as a second-line treatment on its own and as ...
openaire +2 more sources
In May 2003, the US Food and Drug Administration (FDA) granted accelerated approval for the use of the first-in-class proteasome inhibitor bortezomib as a third-line therapy in multiple myeloma, and the European Union followed suit a year later. Bortezomib has subsequently been approved for multiple myeloma as a second-line treatment on its own and as ...
openaire +2 more sources
A review of cancer immunotherapy toxicity
Ca-A Cancer Journal for Clinicians, 2020Lucy Boyce Kennedy
exaly
An update on the immune landscape in lung and head and neck cancers
Ca-A Cancer Journal for Clinicians, 2020Jennifer W Carlisle +2 more
exaly
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Nature Reviews Clinical Oncology, 2021Mariana Paes Dias +2 more
exaly